Stay updated on Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page
- Check4 days agoChange DetectedBoth screenshots show the same study page for NCT01866319, with pembrolizumab vs ipilimumab in advanced melanoma and identical trial details. The changes appear to be cosmetic UI/layout adjustments, not alterations to the study design, eligibility criteria, or reported outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check11 days agoChange DetectedMelanoma and MedlinePlus Genetics were added to the related topics section, representing a minor metadata update to the page. Only related topics metadata were updated; no changes to core content, eligibility criteria, endpoints, or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check25 days agoChange Detected- Removed a MedlinePlus Genetics topic on Melanoma; a deletion of a specific disease-related topic with minimal broader impact.SummaryDifference0.2%

- Check33 days agoChange DetectedUpdated page version to v3.2.0, added MedlinePlus Genetics topic: Melanoma, and included a government funding/operating status notice; removed previous revision reference v3.1.0.SummaryDifference3%

- Check40 days agoChange Detected- Version revision updated from v3.0.2 to v3.1.0. No other content changes detected.SummaryDifference0.1%

- Check54 days agoChange DetectedUpdated to v3.0.2, removed the Melanoma topic from MedlinePlus Genetics, and dropped the Back to Top link and the v3.0.1 reference.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page.